Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Zoom
ZM
|
+$406M |
| 2 |
Baidu
BIDU
|
+$382M |
| 3 |
AGN
Allergan plc
AGN
|
+$366M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$322M |
| 5 |
NextEra Energy, Inc.
NEE
|
+$312M |
Top Sells
| 1 |
Tesla
TSLA
|
+$1.66B |
| 2 |
Meta Platforms (Facebook)
META
|
+$370M |
| 3 |
Pfizer
PFE
|
+$343M |
| 4 |
Gilead Sciences
GILD
|
+$331M |
| 5 |
Amazon
AMZN
|
+$282M |
Sector Composition
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.73% |
| 3 | Consumer Staples | 9.8% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3076
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$340M
| $223K | ﹤0.01% |
+8,300
| New | +$223K |
|
3077
Lineage Cell Therapeutics
LCTX
$295M
| $222K | ﹤0.01% |
+268,400
| New | +$222K |
|
3078
Theriva Biologics
TOVX
$4.04M
| $221K | ﹤0.01% |
2,755
+428
| +18% | +$34.3K |
|
3079
Atara Biotherapeutics
ATRA
$85.4M
| $218K | ﹤0.01% |
+1,024
| New | +$218K |
|
3080
Interparfums
IPAR
$3.49B
| $218K | ﹤0.01% |
+4,713
| New | +$218K |
|
3081
Organogenesis Holdings
ORGO
$639M
| $218K | ﹤0.01% |
67,600
+32,300
| +92% | +$104K |
|
3082
Sol-Gel Technologies
SLGL
$67.1M
| $218K | ﹤0.01% |
3,085
+1,586
| +106% | +$112K |
|
3083
Global X Lithium & Battery Tech ETF
LIT
$1.15B
| $217K | ﹤0.01% |
+10,000
| New | +$217K |
|
3084
Tonix Pharmaceuticals
TNXP
$274M
| – | – |
-1
| Closed | -$375K |
|
3085
Energy Fuels
UUUU
$2.89B
| $217K | ﹤0.01% |
+184,200
| New | +$217K |
|
3086
Yatra Online
YTRA
$91.1M
| $217K | ﹤0.01% |
210,900
+31,700
| +18% | +$32.6K |
|
3087
Zedge
ZDGE
$41.7M
| $217K | ﹤0.01% |
246,714
+7,700
| +3% | +$6.77K |
|
|
MYOV
3088
DELISTED
Myovant Sciences Ltd.
MYOV
| $217K | ﹤0.01% |
+28,700
| New | +$217K |
|
3089
iShares Select Dividend ETF
DVY
$20.9B
| $213K | ﹤0.01% |
+2,900
| New | +$213K |
|
|
LINX
3090
DELISTED
Linx S.A.
LINX
| $212K | ﹤0.01% |
+65,500
| New | +$212K |
|
3091
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.19B
| $209K | ﹤0.01% |
+3,800
| New | +$209K |
|
3092
Armata Pharmaceuticals
ARMP
$107M
| $207K | ﹤0.01% |
66,727
-7,427
| -10% | -$23K |
|
3093
iShares Russell Mid-Cap ETF
IWR
$45.2B
| $207K | ﹤0.01% |
+4,800
| New | +$207K |
|
3094
Oak Valley Bancorp
OVLY
$244M
| $207K | ﹤0.01% |
13,173
+200
| +2% | +$3.14K |
|
3095
Transocean
RIG
$3.07B
| $207K | ﹤0.01% |
178,597
-1,668,603
| -90% | -$1.93M |
|
3096
Solid Biosciences
SLDB
$413M
| $207K | ﹤0.01% |
5,770
+1,901
| +49% | +$68.2K |
|
3097
Urban Outfitters
URBN
$6.43B
| $206K | ﹤0.01% |
+14,500
| New | +$206K |
|
|
LKCO
3098
DELISTED
Luokung Technology Corp Ordinary Shares
LKCO
| $206K | ﹤0.01% |
1,303
+780
| +149% | +$123K |
|
3099
ProQR Therapeutics
PRQR
$231M
| $203K | ﹤0.01% |
37,000
-46,000
| -55% | -$252K |
|
|
YI
3100
111 Inc
YI
$50.2M
| $203K | ﹤0.01% |
+3,065
| New | +$203K |
|